Savara (SVRA) Operating Income (2010 - 2026)
Savara (SVRA) reported Operating Income of -$39.0 million for Q1 2026, down 37.12% year-over-year from -$62.0 million in Q1 2025, and down 16.67% quarter-over-quarter from -$33.4 million in Q4 2025.
Savara (SVRA) Operating Income (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Operating Income data on file, last reported at -$39.0 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$39.0 million, down 37.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$134.1 million (down 22.86% YoY), and the FY2025 annual result was -$123.5 million, down 19.72% from the prior year.
- Operating Income fell to -$39.0 million in Q1 2026 per SVRA's latest filing, from -$33.4 million in the prior quarter.
- Over five years, Operating Income peaked at -$8.0 million in Q1 2022 and troughed at -$39.0 million in Q1 2026.
- A 5-year average of -$21.4 million and a median of -$22.5 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2024: Operating Income gained 22.74% in 2022, then plunged 89.76% in 2024.
- A 5-year view of Operating Income shows it stood at -$10.9 million in 2022, then plunged by 62.11% to -$17.6 million in 2023, then tumbled by 76.82% to -$31.2 million in 2024, then slipped by 7.2% to -$33.4 million in 2025, then slipped by 16.67% to -$39.0 million in 2026.
- Business Quant data shows SVRA's Operating Income at -$39.0 million in Q1 2026, -$33.4 million in Q4 2025, and -$30.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | -38.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.99 Mn |
| Dec 31, 2025 | -33.42 Mn |
| Sep 30, 2025 | -30.26 Mn |
| Jun 30, 2025 | -31.44 Mn |
| Mar 31, 2025 | -28.44 Mn |
| Dec 31, 2024 | -31.17 Mn |
| Sep 30, 2024 | -26.36 Mn |
| Jun 30, 2024 | -23.19 Mn |
| Mar 31, 2024 | -22.48 Mn |
| Dec 31, 2023 | -17.63 Mn |
| Sep 30, 2023 | -18.04 Mn |
| Jun 30, 2023 | -12.22 Mn |
| Mar 31, 2023 | -12.11 Mn |
| Dec 31, 2022 | -10.88 Mn |
| Sep 30, 2022 | -10.54 Mn |
| Jun 30, 2022 | -9.38 Mn |
| Mar 31, 2022 | -8.05 Mn |
| Dec 31, 2021 | -10.64 Mn |
| Sep 30, 2021 | -9.97 Mn |
| Jun 30, 2021 | -10.45 Mn |